CD24 and neoplasm: A phase I clinical trial of the anti-CD24 monoclonal antibody NXA01 has also been approved, and it is noteworthy for its ability to selectively target and kill CD24-positive tumor cells; the outcomes of this trial are eagerly anticipated.